CRISPR: three new developments in the world of gene editing
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
List view / Grid view
In this article, we outline three recent studies that have advanced the potential uses of CRISPR in the biomedical field.
A study has revealed that the microbiome could impact COVID-19 severity and may be implicated in persisting inflammatory symptoms.
A team has found immune cells in the lungs after infection from the flu, which protected mice against reinfection from a different strain.
Researchers show that genomic tracking can be used to trace individual virus transmission lineages and could therefore be adopted for future pandemics.
This webinar from Bio-Techne discusses canonical and alternative oxygen sensing mechanisms implicated in cancer therapy resistance and recurrence.
A new study has revealed a range of genomic, proteomic and transcriptomic data about head and neck cancers, presenting possible treatment strategies.
Researchers have used a novel DNA-editing method to convert one base pair to another, increasing the lifespan of mice with progeria.
In this article, Ramya Sriram describes how data science is driving innovations in medical biotechnology and genomics.
Researchers have shown rhesus macaques and baboons develop strong signs of acute viral infection from SARS-CoV-2, making them ideal models.
Researchers have identified microbes that could affect the way a person metabolises glucose and lipids, leading to a potential treatment for type 2 diabetes.
Researchers were able to eradicate breast cancer in mice when they combined CAR T cells with STING pathway agonists and immunotherapeutic antibodies.
Anthony Finbow explains how applying microbiome-based evidence to disease modelling will enable researchers to devise more targeted treatments.
According to new research, because women have two copies of the ACE2 protein, they are less likely to suffer from severe COVID-19, unlike men who have one copy.
Researchers have shown that neutralising antibodies developed in COVID-19 patients were less potent if from those with severe or fatal disease.
According to researchers, an interaction between host microRNA and SARS-CoV-2 could be responsible for the range of disease severities.